{"nctId":"NCT00619918","briefTitle":"Nebulized Hypertonic Saline for Bronchiolitis","startDateStruct":{"date":"2008-02"},"conditions":["Bronchiolitis"],"count":447,"armGroups":[{"label":"Nebulized 3% Saline","type":"EXPERIMENTAL","interventionNames":["Drug: Nebulized 3% saline"]},{"label":"Nebulized 0.9% Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Nebulized 0.9% saline"]}],"interventions":[{"name":"Nebulized 3% saline","otherNames":["3% saline","Hypertonic saline","NaCl 3%"]},{"name":"Nebulized 0.9% saline","otherNames":["Normal saline","NS","NaCl 0.9%"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* clinical diagnosis of viral bronchiolitis\n* between November and April\n\nExclusion Criteria:\n\n* prematurity \\< 34 weeks\n* chronic lung disease\n* congenital heart disease\n* history of wheezing, asthma or albuterol use\n* tracheostomy status\n* need for intensive care of assisted ventilation","healthyVolunteers":false,"sex":"ALL","maximumAge":"24 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Admission Rate","description":"Patients enrolled in the ED who required inpatient admission. Patients who required admission but were transferred to another facility due to lack of available beds were considered admitted for this outcome. Note, neither study site has an observation unit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"PRIMARY","title":"Length of Stay","description":"Length of stay defined as date of discharge minus date of admission (whole days)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.87","spread":"2.00"},{"groupId":"OG001","value":"2.86","spread":"1.73"}]}]}]},{"type":"PRIMARY","title":"Change in RDAI Score","description":"The Respiratory Distress Assessment Instrument (RDAI) is a respiratory severity score ranging from a low score of 0 to maximum score of 17. Lower scores indicate more mild symptoms; mild disease (0-6), moderate disease (7-11), and severe (12-17). A decrease in score of 2 is considered clinically significant improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.032","spread":"2.087"},{"groupId":"OG001","value":"0.8557","spread":"1.650"}]}]}]},{"type":"SECONDARY","title":"Hours of Oxygen Use","description":"Hours requiring supplemental oxygen for admitted patients.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.88","spread":"39.99"},{"groupId":"OG001","value":"31.39","spread":"44.54"}]}]}]},{"type":"SECONDARY","title":"IV Fluid Use","description":"IV fluid volume administered during entire hospitalization, in mL/kg","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.38","spread":"90.15"},{"groupId":"OG001","value":"59.73","spread":"107.10"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Supplemental Medication Use","description":"patients who received supplemental albuterol, ipratropium, or epinephrine inhaled treatment (other than pre-treatment for study med)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":231},"commonTop":["ICU admission","Worsening cough"]}}}